Takeuchi Hiroya, Ikeuchi Shunji, Kawaguchi Yoshiki, Kitagawa Yuko, Isobe Yoh, Kubochi Kiyoshi, Kitajima Masaki, Matsumoto Sumio
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
World J Surg. 2007 Nov;31(11):2160-7. doi: 10.1007/s00268-007-9219-8.
We hypothesized that preoperative and/or postoperative enteral immune-enhanced formulas that are supplemented with arginine, omega-3 fatty acids, and RNA may reduce postoperative complications in patients undergoing esophagectomy for thoracic esophageal squamous cell carcinoma (ESCC).
Forty patients who underwent esophagectomy were divided into three groups: group A (n = 20) received a control enteral diet (Erental) through the jejunostomy after surgery. group B (n = 6) received an enteral diet supplemented with immune-enhancing substrates (Impact) containing arginine, omega-3 fatty acids, and RNA after surgery. group C (n = 14) received the impact before and after surgery.
Lymphocyte counts in group C on postoperative day (POD) 7 were somewhat higher than that in group A (p = 0.07) and significantly higher than in group B (p = 0.03). Furthermore the incidence of incisional wound infection in group C was significantly lower than that in group A (p = 0.03). Moreover, the duration of postoperative systemic inflammatory response syndrome (SIRS) was significantly shorter in group C than in group A (p < 0.05).
This study reveals that the perioperative immune-enhanced formula may be superior to postoperative control enteral formulas in terms of reducing surgical wound infection and postoperative SIRS, which may result in serious postoperative complications for patients who have undergone esophagectomy.
我们假设术前和/或术后补充精氨酸、ω-3脂肪酸和RNA的肠内免疫增强配方可能会减少胸段食管鳞状细胞癌(ESCC)患者行食管切除术后的并发症。
40例行食管切除术的患者被分为三组:A组(n = 20)术后通过空肠造口接受对照肠内饮食(能全力)。B组(n = 6)术后接受补充了含精氨酸、ω-3脂肪酸和RNA的免疫增强底物的肠内饮食(安素)。C组(n = 14)在手术前后均接受安素。
术后第7天(POD 7)C组的淋巴细胞计数略高于A组(p = 0.07),且显著高于B组(p = 0.03)。此外,C组的切口感染发生率显著低于A组(p = 0.03)。而且,C组术后全身炎症反应综合征(SIRS)的持续时间显著短于A组(p < 0.05)。
本研究表明,围手术期免疫增强配方在减少手术伤口感染和术后SIRS方面可能优于术后对照肠内配方,对于行食管切除术的患者,术后SIRS可能导致严重的术后并发症。